Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.
Eur J Obstet Gynecol Reprod Biol
; 222: 84-88, 2018 Mar.
Article
em En
| MEDLINE
| ID: mdl-29408752
ABSTRACT
OBJECTIVES:
The aim of this study was to evaluate the pharmacoeconomic profile in Italy of preoperative treatment with ulipristal acetate at the dose of 5â¯mg/day for 13 weeks in comparison with placebo prior to surgical management of symptomatic uterine fibroids. STUDYDESIGN:
The pharmacoeconomic analysis was based on the calculation of incremental cost-effectiveness ratio (ICER). Effectiveness data were derived from the randomized-controlled trial PEARL-1, whilst costs data were retrieved from the published literature. A Markov model was employed to simulate the pattern of costs and two univariate sensitivity analyses tested the robustness of the results.RESULTS:
In comparison with placebo, ulipristal acetate 5â¯mg for presurgical therapy was estimated to be associated with an incremental cost of 351 per patient. Costs per patient were 3836 for ulipristal acetate vs 3485 for placebo. The incremental effectiveness was 0.01931 QALYs per patient (around 7 quality-adjusted days per patient). Hence, the cost effectiveness ratio was calculated to be 18,177 per QALY gained.CONCLUSIONS:
Preoperative use of ulipristal acetate 5â¯mg in patients with uterine fibroids has a favourable pharmacoeconomic profile.Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
/
Financiamentos_gastos
Bases de dados:
MEDLINE
Assunto principal:
Neoplasias Uterinas
/
Cuidados Pré-Operatórios
/
Leiomiomatose
/
Modelos Econômicos
/
Anticoncepcionais Orais Hormonais
/
Leiomioma
/
Norpregnadienos
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Health_economic_evaluation
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
Aspecto:
Patient_preference
País/Região como assunto:
Europa
Idioma:
En
Revista:
Eur J Obstet Gynecol Reprod Biol
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Itália